Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal versus intravenous lorazepam for acute pediatric status epilepticus
IRCT20250602066039N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of lorazepam in status epilepticus (SE) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Seizure cessation time, Seizure recurrence at 1 hour and 8 more. Started Sep 2026; status: recruiting.
02
Drugs
lorazepam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on IRCT20250602066039N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250602066039N1.